- Home
- GSL vs LENZ Comparison
GSL vs LENZ Comparison
Compare GSL & LENZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GSL
- LENZ
- Stock Information
- Founded
- GSL 2007
- LENZ 2019
- Country
- GSL Greece
- LENZ United States
- Employees
- GSL N/A
- LENZ N/A
- Industry
- GSL Marine Transportation
- LENZ Medicinal Chemicals and Botanical Products
- Sector
- GSL Consumer Discretionary
- LENZ Health Care
- Exchange
- GSL Nasdaq
- LENZ Nasdaq
- Market Cap
- GSL 945.2M
- LENZ 819.1M
- IPO Year
- GSL 2006
- LENZ 2021
- Fundamental
- Price
- GSL $27.95
- LENZ $35.48
- Analyst Decision
- GSL Strong Buy
- LENZ Strong Buy
- Analyst Count
- GSL 1
- LENZ 5
- Target Price
- GSL $30.00
- LENZ $41.80
- AVG Volume (30 Days)
- GSL 342.4K
- LENZ 309.3K
- Earning Date
- GSL 08-04-2025
- LENZ 05-07-2025
- Dividend Yield
- GSL 7.53%
- LENZ N/A
- EPS Growth
- GSL 20.64
- LENZ N/A
- EPS
- GSL 10.54
- LENZ N/A
- Revenue
- GSL $715,232,000.00
- LENZ N/A
- Revenue This Year
- GSL $3.22
- LENZ N/A
- Revenue Next Year
- GSL N/A
- LENZ $544.79
- P/E Ratio
- GSL $2.62
- LENZ N/A
- Revenue Growth
- GSL 3.83
- LENZ N/A
- 52 Week Low
- GSL $17.73
- LENZ $16.54
- 52 Week High
- GSL $28.08
- LENZ $38.93
- Technical
- Relative Strength Index (RSI)
- GSL 69.67
- LENZ 68.67
- Support Level
- GSL $26.80
- LENZ $31.01
- Resistance Level
- GSL $27.60
- LENZ $32.79
- Average True Range (ATR)
- GSL 0.57
- LENZ 2.00
- MACD
- GSL 0.06
- LENZ 0.48
- Stochastic Oscillator
- GSL 99.61
- LENZ 93.76
About GSL Global Ship Lease Inc New
Global Ship Lease Inc operates in the container shipping industry. The company owns and charters out containerships under long-term, fixed-rate charters to container liner companies. The majority of the company's revenues are derived from charters to MAERSK. Its fleet consisted of more than 60 containerships.
About LENZ LENZ Therapeutics Inc.
LENZ Therapeutics Inc is a late-stage biopharmaceutical company focused on developing and commercializing therapies to improve vision and developing ophthalmic pharmaceutical products.. Its initial focus is the treatment of presbyopia, the inevitable loss of near vision that impacts the daily lives of nearly all people over 45.